Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.
about
Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthmaLong-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adultsLong-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroidLong-acting beta2-agonists for stable chronic asthmaEffects of formoterol inhaled dry powder on exercise performance in chronic obstructive pulmonary disease: a single-center, randomized, double-blind, placebo-controlled, crossover study.Asthma--the changing face of drug therapy.Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform(®)) for the treatment of asthma.Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature.Combined budesonide/formoterol turbuhaler treatment of asthma.Formoterol: a review of its use in chronic obstructive pulmonary disease.Budesonide-formoterol (inhalation powder) in the treatment of COPD.Formoterol in the management of chronic obstructive pulmonary disease.Role of arformoterol in the management of COPDRole of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.β2-Adrenergic receptor agonist administration promotes counter-regulatory responses and recovery from hypoglycaemia in ratsBudesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.A review of mometasone furoate / formoterol in the treatment of asthma.Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma.Budesonide + formoterol fumarate dihydrate for the treatment of asthma.Assessing the viability of long-acting β2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective.Modulite technology in the development of formoterol HFA pMDI: clinical evidence and future opportunities.Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults.Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer.
P2860
Q24235964-F31CCF62-9B24-4AF4-A324-6CE6E76C5CEFQ24245643-D296C52F-E149-461F-84F3-7F33C5567B17Q24245719-C925C6AD-EFF8-4A2E-B322-C4F18FF10B05Q24246441-DA885E0F-956C-4BE2-8C6F-0AB80E3B7950Q24247926-0E0A76C1-50D2-4A50-81E9-BC869B8A7421Q33738892-F285F7FC-3A36-4F85-99B4-55C19067B9D1Q33930453-731DFBFC-C320-40C8-8DD0-08CFE06EC40EQ34338085-C471AC87-2514-4023-B589-F6F22DF87A9CQ34834664-2664001D-F32E-490F-B26D-3ABCF09267C3Q35009462-06589761-E765-4084-965D-77B2497F2A92Q35627824-AEBB92D9-0898-4DCB-A392-794B55F2974EQ37018887-17C401F8-7CE8-40B0-AE6E-164667F13975Q37070307-83B7F5CA-3A66-4315-84EB-7DB970C336F9Q37070335-B620406A-513C-4F67-8362-9E839A317A39Q37129351-45A6E034-9179-4B39-8907-878D502CC756Q37380232-C738D4F8-13C5-44EF-AAB8-4E3D7CB13025Q37982436-D0CEAB41-01FA-4626-BF29-DC551345769EQ38077842-05028FD6-FD5F-480B-AC0D-3DEE253CDD2BQ38080476-38BCB624-53FA-4384-90B7-BC9F3DDB34B0Q38806274-1BF75DAF-2FD9-44A7-B771-2F97BAB86507Q38951196-86B5B58F-B7C8-4F24-9DD7-9A92B5C7ECA9Q40129417-9CB4E2B4-6D19-46D8-9A51-A4BB8DE69969Q43912252-45378565-BB78-4606-8A4E-8187579B55DAQ44161807-5CEEBDDD-ADBC-40B0-9CC0-8983E02670C5Q46196657-21166E1D-F81B-47BA-A8BD-10EF095F8DD0Q46486322-6E03A96B-CD2D-4051-AB0F-83877877451FQ46908051-8BB4896D-CF80-415C-BE7D-15721B76F1F2
P2860
Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Formoterol. An update of its p ...... y in the management of asthma.
@ast
Formoterol. An update of its p ...... y in the management of asthma.
@en
Formoterol. An update of its p ...... y in the management of asthma.
@nl
type
label
Formoterol. An update of its p ...... y in the management of asthma.
@ast
Formoterol. An update of its p ...... y in the management of asthma.
@en
Formoterol. An update of its p ...... y in the management of asthma.
@nl
prefLabel
Formoterol. An update of its p ...... y in the management of asthma.
@ast
Formoterol. An update of its p ...... y in the management of asthma.
@en
Formoterol. An update of its p ...... y in the management of asthma.
@nl
P1433
P1476
Formoterol. An update of its p ...... y in the management of asthma.
@en
P2093
R A Bartow
P304
P356
10.2165/00003495-199855020-00016
P577
1998-02-01T00:00:00Z
P6179
1018055932